These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 24692038)

  • 1. Authors' response re: Clarifying costs and benefits of respiratory syncytial virus immunoprophylaxis.
    Meissner HC; Kimberlin DW
    Pediatrics; 2014 Apr; 133(4):e1101-3. PubMed ID: 24692038
    [No Abstract]   [Full Text] [Related]  

  • 2. Clarifying costs and benefits of respiratory syncytial virus immunoprophylaxis.
    McLaurin K; Ambrose CS
    Pediatrics; 2014 Apr; 133(4):e1101. PubMed ID: 24692037
    [No Abstract]   [Full Text] [Related]  

  • 3. RSV immunoprophylaxis: does the benefit justify the cost?
    Meissner HC; Kimberlin DW
    Pediatrics; 2013 Nov; 132(5):915-8. PubMed ID: 24127478
    [No Abstract]   [Full Text] [Related]  

  • 4. Antibody against RSV helps prevent wheeze in infants.
    BMJ; 2013 May; 346():f3089. PubMed ID: 23678095
    [No Abstract]   [Full Text] [Related]  

  • 5. Respiratory syncytial virus and recurrent wheeze.
    Blanken MO; Rovers MM; Bont L;
    N Engl J Med; 2013 Aug; 369(8):782-3. PubMed ID: 23964947
    [No Abstract]   [Full Text] [Related]  

  • 6. Respiratory syncytial virus and recurrent wheeze.
    Brand PL
    N Engl J Med; 2013 Aug; 369(8):782. PubMed ID: 23964948
    [No Abstract]   [Full Text] [Related]  

  • 7. Respiratory syncytial virus infection is linked to recurrent wheezing in healthy premature infants.
    Escobar GJ
    J Pediatr; 2013 Nov; 163(5):1531. PubMed ID: 24160662
    [No Abstract]   [Full Text] [Related]  

  • 8. Respiratory syncytial virus prophylaxis reduces chronic respiratory morbidity in prematurely born infants.
    Greenough A
    Evid Based Med; 2014 Apr; 19(2):65. PubMed ID: 24142143
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants.
    Yoshihara S; Kusuda S; Mochizuki H; Okada K; Nishima S; Simões EA;
    Pediatrics; 2013 Nov; 132(5):811-8. PubMed ID: 24127479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Infections with RS viruses in children].
    Krankenpfl J; 2004; 42(7-10):231. PubMed ID: 15675393
    [No Abstract]   [Full Text] [Related]  

  • 11. Early-life wheezing and respiratory syncytial virus prevention.
    Lemanske RF
    N Engl J Med; 2013 May; 368(19):1839-41. PubMed ID: 23656652
    [No Abstract]   [Full Text] [Related]  

  • 12. Respiratory syncytial virus trials and beyond.
    Mazur NI; van Delden JJ; Bont LJ
    Lancet Infect Dis; 2015 Dec; 15(12):1363-5. PubMed ID: 26511957
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus.
    Meissner HC; Bocchini JA; Brady MT; Hall CB; Kimberlin DW; Pickering LK
    Pediatrics; 2009 Dec; 124(6):1676-9. PubMed ID: 19948632
    [No Abstract]   [Full Text] [Related]  

  • 14. [Experience of palivizumab in prophylaxis of respiratory syncytial viral infection in premature children with bronchopulmonary dysplasia].
    Aliamovskaia GA; Keshinian ES
    Vestn Ross Akad Med Nauk; 2012; (12):30, 32-4. PubMed ID: 23530423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: recommendation for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease.
    Onuzo OC
    Cardiol Young; 2004 Aug; 14(4):466-7; author reply 467-9. PubMed ID: 15680062
    [No Abstract]   [Full Text] [Related]  

  • 16. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
    Simoes EA; Groothuis JR; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick LM; Kimpen JL;
    J Pediatr; 2007 Jul; 151(1):34-42, 42.e1. PubMed ID: 17586188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks.
    Blanken M; Rovers M; Sanders E; Bont L
    Contemp Clin Trials; 2012 Nov; 33(6):1287-92. PubMed ID: 22820319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection.
    Gutfraind A; Galvani AP; Meyers LA
    JAMA Pediatr; 2015 Apr; 169(4):341-8. PubMed ID: 25706618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants.
    Blanken MO; Rovers MM; Molenaar JM; Winkler-Seinstra PL; Meijer A; Kimpen JL; Bont L;
    N Engl J Med; 2013 May; 368(19):1791-9. PubMed ID: 23656644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Polivizumab against respiratory syncytial virus?].
    Brunvand L
    Tidsskr Nor Laegeforen; 2000 Sep; 120(21):2570-2. PubMed ID: 11070999
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.